Infliximab vs Adalimumab: Which Is Best for Behçet Syndrome?

Both infliximab and adalimumab were found to be effective in achieving remission and enhancing quality of life while having a high level of tolerability in patients with mucocutaneous Behçet syndrome.
Medscape Medical News